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bstract
MR-PET is a novel imaging modality that combines anatomic and metabolic data acquisition, allowing for simultaneous depiction of morpho-
ogical and functional abnormalities with an excellent soft tissue contrast and good spatial resolution; as well as accurate temporal and spatial
mage fusion; while substantially reducing radiation dose when compared with PET-CT.In this review, we will discuss MR-PET basic principles and technical challenges and limitations, explore some practical considerations, and
over the main clinical applications, while shedding some light on some of the future trends regarding this new imaging technique.
 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The development of Magnetic resonance-Positron Emission
omography (MR-PET) has been a logical next step follow-
ng the success of Positron Emission Tomography-Computed
omography (PET-CT). The basis of both approaches is the
ombination of the relatively low spatial resolution functional
nformation provided by PET superimposed on the higher spatial
esolution of a 3D tomographic technique, such as CT or MRI.
e CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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he intrinsic qualities of MRI that have driven the development
f this combination are the higher intrinsic tissue contrast and
he lack of medical radiation.
Since its introduction, hybrid PET-CT has modified the appli-
ability of PET use in clinical practice. The added value of
natomic localization and morphologic characterization pro-
ided by CT allowed improved diagnostic accuracy. The
dvantages of PET-CT, based on hardware-derived registration
f the two modalities, has not only largely replaced PET-only
canners in clinical routine, but expanded considerably the clin-
cal and research roles. The major drawback is the high radiation
xposure, combining the X-ray radiation of CT with the gamma
adiation and radioactive decay of PET.
The success of PET-CT has fostered the interest in using
R as a replacement for CT in a hybrid scanner [1,2]. The
natomical landmarks can also be achieved with MRI, with sev-
ral potential benefits. These include: improved co-registration
f PET and anatomic MR images as MRI data can be simulta-
eously acquired, unlike the sequential data acquisition with CT;
mproved soft-tissue contrast resolution compared to CT; and
eduction in overall radiation exposure. MRI does not employ
onizing radiation, which is particularly problematic in circum-
tances of anticipated multiple follow-up studies or in imaging
oung patients.
MRI provides additional quantitative information regarding
issue function with specific techniques (diffusion, spectroscopy,
tc.) and cell-specific contrast agents.
Despite these appropriate rationales, the transition from PET-
T to MR-PET is not simple: the clinical value of PET-CT
as already been firmly established, with extensive publications
nd wide clinical use [3–6]; financial concerns of replacing a
ery expensive imaging modality with an even more expensive
ne; the natural tendency of practicing imaging specialists to be
esitant to learn a new modality; and the major technical chal-
enges yet to be resolved, such as the compatibility between PET
omponents and MR magnetic field.
To date, the readout technology (electronics of the
ET scintillation detectors) is not MR-compatible; as the
hotomultiplier-based PET scanners do not readily work within
r near the magnetic environment of a MR scanner [7]. MR data,
nlike that acquired with CT, are not readily usable for attenua-
ion correction (AC) [8–10], limiting quantification of PET data
11].
In this review we will discuss the imaging aspects and chal-
enges of MR-PET and initial comparison with PET-CT as well
s both current and projected clinical applications.
.  Photomultipliers  in  the  magnetic  environment  of  MR
Compatibility between the photomultipliers, integral in PET
maging, and MR system has been particularly challenging. A
urrent solution is provided in the Biograph mMR (Siemens
edical systems, Erlangen, Germany). In this system, the PETetectors are fully integrated into a 3 Tesla MR system within a
ingle gantry. Photomultipliers were replaced with avalanche
hotodiode technology, which are less sensitive to magnetic
elds. This system design enables simultaneous acquisition of
s
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ET and MR data [12–14]. A second method of hybrid MR-
ET system uses sequential acquisition mode (Ingenuity TF
R-PET, Phillips, Eindhoven, the Netherlands). However, data
cquisition with this system is fundamentally the same as with
ET-CT, and sacrifices one of the great advantages that MR-PET
an offer, which is simultaneous acquisition.
Simultaneous measurement with MR-PET has been consid-
red one of its strongest features, leading to superior spatial and
emporal co-registration of the two modalities; offering a wealth
f complementary anatomical, physiological, and molecular
nformation; while considerably shortening scan time compared
o separate acquisitions [15].
.  Attenuation  correction  of  PET  data  by  MR  data
For quantitative PET imaging, the reconstructed data needs
o be corrected for -photon attenuation. Direct measurement
f linear attenuation coefficients is not possible in integrated
ET-MR systems. MR information has to be converted to lin-
ar attenuation coefficients; however, because the MR signal
eflects proton density instead of photon attenuation, this con-
ersion is challenging. As MR does not provide an attenuation
ap for ionizing radiation, PET data in a MR-PET system can-
ot be subjected to AC, which renders the PET data qualitative
mages only. Attenuation correction is mandatory for quanti-
ative assessments with standardized uptake values (SUVs) or
adiotracer kinetics [16,17].
Current MR-based attenuation algorithms are founded on the
se of a dedicated MRI sequence followed by segmentation-
ased algorithms to derive three or four tissue classes, excluding
one (see below) [18]. The three-segment model accounts for
ir, soft tissues, and lungs [16,19]; while the four-segment model
ccounts for air, soft tissues (muscles and solid organs), fat, and
ungs [9]. These models are based on T1-weighted multi-station
poiled gradient echo (GRE) or T1-weighted 2-point Dixon
equences (Fig. 1), respectively. The four-segment model is cur-
ently in use in simultaneous Biograph mMR hybrid scanners.
The Dixon sequence divides the body into four distinct tissue
ypes based directly on the MR image intensity. These tissues
re then assigned a corresponding linear attenuation coefficient
ased on known densities. Mineralized bone has a higher linear
ttenuation coefficient for 511 keV photons than soft tissues but
s not represented in Dixon-based MR attenuation methods. Cor-
ical bone has a much faster transverse relaxation rate than soft
issues, and hence any signal produced within traditional MR
equences disappears prior to sampling. As a result, the Dixon-
ased attenuation correction method does not take cortical bone
nto consideration and is less robust for osseous lesions [20].
The end product of the Dixon-based technique is four
equences: in-phase, opposed-phase, fat-only, and water-only
mages. All 4 images are combined to create a   map, which is
sed for attenuation correction.
The Dixon sequence is a 20 s duration free-breathing
equence acquired during the first 20 s of the PET scan.
lternative algorithms involving population-based atlases [21],
ltra-fast MR sequences for bone derivation [22], or co-
egistered CT information [23] have been proposed; however,
30 M. Ramalho et al. / European Journal of Radiology Open 1 (2014) 28–39
Fig. 1. Soft tissue AC based on MR imaging. In-phase (A) out-of-phase (B) 2-point Dixon images from attenuation correction sequences. Resulting Map (C)
providing separate water/fat images that serve as basis for soft tissue segmentation that can be assigned to a PET attenuation map. Resulting attenuation corrected
whole-body PET scan (D).
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one of these have yet been adopted into routine MR-PET.
C needs to be improved further, before MR-PET can be used
eproducibly for quantitative PET imaging [24].
.  MR-PET  workﬂow
A specific challenge in MR-PET is how to develop an opti-
ized workflow. Whole-body MR-PET imaging and sequence
ptimization must be addressed from a clinical and patient
erspective. Whole-body MR-PET should be fast enough to
ompete with PET-CT (study length approximately 20 min),
hile providing added clinical value over PET-CT or MRI alone
20].
MR-PET scans take considerably longer than PET-CT scans
or a number of reasons. Patient positioning takes longer on the
able because coils have to be placed on top of the patient for the
R portion of the examination and MR sequences are longer in
uration. Additionally, multiple different data acquisitions are
cquired with MRI compared with CT, which employs a single
cquisition with faster data accumulation [3]. The tendency of
cquiring multiple different types of data acquisitions is a carry-
ver of MR practice in general. Although this is certainly one of
he great strengths of MR and contributes to its superiority over
T in many settings, it comes at the expense of longer study
imes.
In spite of flexibility seen with diagnostic MRI in general,
 specific tailor-designed imaging protocol is recommended in
rder to be fast enough without compromising the image quality
equired to achieve high diagnostic accuracy. Another important
spect to tailor MR-PET protocols short is to render the study
conomical viability.
The imaging protocols and workflow are dependent on the
esign and the type of the MR-PET unit. In simultaneous MR-
ET systems, the image acquisition of PET and MRI can occur
oncurrently for a given bed position. In the sequential approach,
RI is performed either before or after PET data acquisition.
t is important to note that, depending on the type of sequences
sed, some sequences must run separately from the PET data
cquisition in the simultaneous MR-PET systems, as many of
he sequences used in body MRI rely on breath-hold acquisitions
25].
To a large extent, as a reflection of the newness of the hybrid
odality, there are currently no universally accepted standard
rotocols for MR-PET [26–29]. Protocols likely will have to
e tailored to specific disease entities. For example, in settings
here imaging the liver for disease is crucial, dynamic imaging
f the liver will be mandatory, as MRI is superior in character-
zation and detection of liver lesions compared to either CT or
ET alone (Fig. 2).
Although most of the organ-based protocols may initially be
imilar to standard protocols for MRI-only examinations, it will
ave to be determined to what extent MRI can be condensed to be
 “minimum necessary” protocol, with the maximum diagnos-
ic outcome reflecting the addition of PET data [30]. Likewise,
dvanced MR imaging techniques such as MR spectroscopy,
iffusion-weighted, perfusion imaging and functional MR imag-
ng, can provide relevant diagnostic information; however, they
a
P
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annot be applied to whole-body imaging. Specific imaging
equences may have to be restricted to organs and body sections
hat benefit most from such imaging protocols (Fig. 3) [31].
A whole-body examination can be performed with five bed
ositions covering the head, neck, thorax, abdomen, and pelvis
p to the thighs. Each bed position typically lasts 3–4 min to
cquire the PET component, leading to a whole-body examina-
ion time of about 15–20 min for PET data. Strictly adhering to
he time duration of PET acquisition, only 2 or at most 3 MR
equences can be obtained at each bed position. If one employs
 normal diagnostic, yet still abridged, MR scan of the whole
ody; about 60–90 min is needed to cover all this territory with
 sufficient range of MR sequences.
Optimized pulse sequences must provide at least as much
nformation as low-dose unenhanced CT studies. This is usu-
lly done with three-dimensional T1-weighted 2-point Dixon
hat takes approximately 20 s per image stack and position. In
act, fat-suppressed T1-weighted images look very similar to
re-contrast CT images, with the major visual difference being
hat cortical bone. The use of Dixon sequences alone, for both
C and anatomic localization (Fig. 4), without additional MR
equences, can be done quickly enough to compete with PET-CT
32]; however, this method does not adequately utilize the added
alue of MRI [30]. One study compared the diagnostic perfor-
ance of MR-PET against PET-CT by using a short examination
ime (<20 min) and using Dixon sequences for both, AC and
natomic localization [32], showing comparable reliability of
R-PET and PET-CT without significant differences regarding
esion detection. Tracer uptake in lesions and background corre-
ated well between MR-PET and PET-CT. One subsequent study
y Jeong et al. [33] compared the Dixon sequence on hybrid MR-
ET with contrast-enhanced PET-CT for PET-positive lesions in
atients with oncologic diseases. SUVs of PET-positive lesions
orrelated well between MR-PET and contrast-enhanced PET-
T; however, Dixon images provided less anatomic information
f PET images, recommending additional MR sequences to
mprove anatomic information (Fig. 5).
In our approach to the MR-PET workflow, we currently use
 combination of whole-body imaging based on pre-contrast
nd post-contrast imaging using the Dixon sequence, radial
1-weighted 3D-GRE, short-tau inversion recovery (STIR), T2-
LADE, or half-Fourier acquisition single-shot turbo spin-echo
HASTE) sequences; complemented by an organ-based imaging
rotocol. Depending on the body region of interest, a dedicated
rgan-based protocol is followed by a whole-body acquisition,
hich typically adds around 10 min to the total examination
ime. Pediatric patients represent a particular population where
he imaging protocols for MR-PET should be kept as simple
s possible to maintain patient tolerance. Free-breathing radial
echniques, such as radial 3D GRE (T1-weighted) or BLADE
T2-weighted) are preferred, especially for the thoracic region
nd upper abdomen because their robustness to motion and due
o the possibility of being acquired in a free-breathing fashion
long the PET acquisition. Our approach for fusion of MR and
ET data is based on the fact that PET data is acquired in a
ree-breathing manner, while many of the MR sequences we
mploy in MRI are breath-hold; therefore, as a result we have
32 M. Ramalho et al. / European Journal of Radiology Open 1 (2014) 28–39
Fig. 2. Colorectal cancer follow-up. Axial contrast-enhanced CT (A), PET (B), and PET-CT (C) images. Axial contrast-enhanced T1-weighted VIBE MR on the
arterial (D) and portal phase (E), PET (F); fused PET-T1-weighted VIBE MR (G), Fat-suppressed T2 TSE (H). A new solitary hypervascular liver lesion is seen
between segments # VII and # VIII on MR images (D, F). The combination of mild T2-signal intensity (arrow, H), arterial hyper-enhancement (arrow, D) and fading
in portal phase allowed the diagnosis of metastasis. This lesion is not seen on contrast-enhanced CT (A). PET images do not contribute to diagnostic accuracy.
Fig. 3. Distal metastasis in a patient with recurrent ovarian cancer post-surgery. Axial unenhanced CT (A), PET (B), and PET-CT (C) images. Axial T2-weighted
HASTE MR (D), PET (E), and Axial fused PET-T2-weighted HASTE MR (F). There is a small, round right retrocrural lymph node, which is appreciated on CT
and MRI, and demonstrates intense FDG uptake on both PET acquisitions (arrowhead, A–F) in keeping with nodal metastasis. There is also a focal area of mildly
increased signal intensity on HASTE, with corresponding focus of intense FDG uptake on the PET acquired with MR, involving the submucosal of the gastric antrum
(arrow, D–F) suspicious for submucosal gastric metastasis. There is no corresponding CT or CT PET abnormality (A–C). Patient also has significant, FDG-avid,
local recurrent disease (not shown).
M. Ramalho et al. / European Journal of Radiology Open 1 (2014) 28–39 33
Fig. 4. Relapse of acute myeloid leukemia (AML) after haploidentical allogeneic stem cell transplant. Coronal fused MR-PET with in-phase 2-point Dixon images
f use re
i , B).
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F
H
irom attenuation correction sequences (A–C). Intense uptake is seen with diff
nvolvement at the brachial plexus, which is more pronounced at the right (arrow
he excellent registration between the two modalities.
ncorporated novel breathing-averaged MR sequences for the
urpose of accurate data fusion (see next section).
Other strategies of data acquisition are described in the liter-
ture for reference [26,27,29,34–37]. r
ig. 5. Incidental renal cancer. Axial unenhanced CT (A), PET (B), and PET-CT (C) i
ASTE MR (F). A right kidney mass show intense uptake in both PET datasets (B, E
n seen on HASTE MR (D). Fused PET-CT (C) and MR-PET (F) confirm the malignplacement of bone marrow (arrows, A). The patient has also leukemic nerve
 Pancreatic and mammary involvement were already depicted (arrow, C). Note
.  Motion  correctionThe expected benefit of an integrated MR-PET system
equires adequate superimposition of image data sets, as
mages. Axial T2-weighted HASTE MR (D), PET (E); fused PET-T2-weighted
). This lesion is not apparent on unenhanced CT (A), and improved delineation
ant nature.
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recise anatomic correlation between tracer-avid tissue and
he anatomic detail derived from MRI images is necessary
26]. Registration software continues to evolve, but still at
resent do not achieve satisfactory results, especially in the
ody [38]. Software fusion of PET and MR images suffer from
imitations, such as partial volume effects, different spatial
esolutions between MR and PET, and physiologic motion with
on-rigid structures. The fusion of brain images is relatively
traightforward owing to its rigid structure (i.e., only rotation
nd translation) and lack of breathing-related or cardiac-related
otion artifact. The territories that experience the greatest
hallenge for fusion are regions that represent non-rigid
tructures (i.e., can change shape) that experience physiologic
otion, such as the thorax, abdomen and pelvis [39–41].
Manual re-registration of the upper abdomen can be chal-
enging because of the relative paucity of internal landmarks
42,43].
To correct for the motion that abdominal organs undergo dur-
ng respiration, several strategies have been described [44–46].
ree-breathing PET data acquisition is the standard approach
or whole-body examinations on PET-CT and MR-PET. Histor-
cally, free-breathing acquisition is not ideal for MR sequences,
hich are sensitive to motion artifact. The trend of body MRI
or the last 20 years has been to move toward breath-hold or
ingle-shot type sequences, to minimize motion. Pairing free-
reathing PET data with acquisition of MR data at the end
f quiet expiration (similar to what it is done with PET-CT)
ight be one solution, as it has been shown with PET-CT to
esult in only minor misregistration. This strategy might be
ccomplished with breath-hold sequences such as T1-weighted
D volumetric interpolated breath-held examination (VIBE)
nd fast spin echo T2-weighted sequences or with respira-
ory gated or navigated T2-weighted and diffusion-weighted
mages (DWI). Respiratory-gated T1-weighted sequences are
easible, but require unacceptably long acquisition times [47].
2-weighted sequences may be acquired in a free-breathing
anner with reasonable image quality using a snap shot type
equence such as HASTE; however, unpredictable misregis-
ration between slices occur, if navigator-triggered pulses are
ot employed. Other sequences that can be acquired in a free-
reathing manner and with acceptable image quality include
ree-breathing STIR and DWI, but they are also subjected to
npredictable misregistration between slices.
A further approach is the use of respiratory-gated acquisition
f PET data [48–51]. However, this form of motion correction
enerates a final image that is reconstructed from only a portion
f the total useful counts. The end result is an image that either
uffers from reduced SNR or requires a very long acquisition to
ecoup counts and image quality, making this option inefficient
or whole-body imaging [20].
Ongoing research evaluates other approaches, which
nclude: a navigated 3D-GRE T1-weighted experimental
equence [47,52,53]. This technique acquires data when the
avigator-determined position of the diaphragm falls within
he acceptance window positioned during end-expiration.
autious assessment of navigated techniques was provided by
rendle et al. [54], who showed that MR-based gated PET with
l
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nd-expiratory attenuation correction map did not improve the
lignment quality, but instead added a higher noise level.
The option we favor is the use of MR sequences that are
btained during free breathing but experience higher imager
uality through the use of radial k-space filling of data and do not
equire demanding motion compensation methods. Other inves-
igators have validated this approach; Rakheja et al. [55] showed
hat MR-PET using T1-weighted radial 3D-GRE sequences had
ore accurate spatial registration than PET-CT images. This is
ikely attributable both to the simultaneous acquisition of PET
nd MR data in a whole-body MR-PET system, compared to the
equential acquisition in a PET-CT system.
.  Comparison  with  PET-CT  and  early  clinical
xperience  in  body  applications
Potential clinical applications of MR-PET in body imag-
ng include predominantly the fields of adult and pediatric
ncology where PET-CT is already established. In terms of
orkflow and logistics, MR-PET offers the prospect to spare
ne additional examination. Nonetheless, it has to be evaluated
hich patient population is suitable for this new hybrid modal-
ty. Certainly, some patients will profit from this new imaging
odality, such as children or young adults with anticipated mul-
iple follow-up studies; as in patients with Hodgkin’s disease,
alignant melanoma, or sarcoma, in strive to reduce radiation
xposure. Other application fields, such as neurology, cardio-
ascular disease, and therapy planning and response monitoring
re now under initial evaluation. Current efforts in determin-
ng the performance of MR-PET in oncologic imaging focus
n the prospective intra-individual comparison with PET-CT
26]. Initial results have been very encouraging, indicating some
dvantages for MR-PET, but almost all showing at least equiv-
lent diagnostic performance to PET-CT.
In this section, we briefly review some of the current evidence
egarding the comparison of MR-PET with PET-CT in various
ncologic processes.
.  General  oncology
In oncology, PET-CT is the mainstay in routine clinical
ractice. Given the very recent clinical accessibility of MR-PET,
imited data is still available regarding the diagnostic perfor-
ance of MR-PET for selected clinical indications [32,56–59].
verall lesion detection rates in these studies showed high
orrelation values for detection of PET-positive lesions in PET-
T as well as MR-PET [32,56–59]. Quantification of lesion
ctivity with PET-CT compared with MR-PET, showed in some
tudies lower SUVs for MR-PET. Potential reasons for these
ifferences are inherent to the study design: In all comparison
tudies PET-CT has been performed first, then followed by
R-PET. Consequently, the advanced tracer metabolism and
io-distribution over time might have had an influence on
esion quantification. Another potential source of error is the
R-based AC [60]. Nevertheless, a recent study by Al-Nabhani
t al. [61] showed no significant qualitative or quantitative dif-
erences between MR-PET and PET-CT. The PET data on both
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odalities were similar; furthermore, they observed superior
oft-tissue resolution of MR imaging in head and neck, pelvis,
nd colorectal cancers; and of CT in lung and mediastinal nodal
isease, pointed to future tailored use in these locations.
A major concern in staging is the detection of lung metas-
asis or lung cancer staging and follow-up, since CT is known
o be superior to MRI in the evaluation of the lung parenchyma
62]. Initial results are available on direct comparison between
R-PET and PET-CT in the staging of lung cancer, mostly
on-small-cell lung cancer; however, many of these studies are
imited by small sample size [63–65]. Schwenzer et al. [63]
eported on ten patients with lung cancer and compared PET-
T with MR-PET, and concluded that lesion characterization
nd tumor detection were similar in most patients.
The performance of MR-PET has also been studied for the
etection of pulmonary nodules [66]. Using simultaneous PET
nd a free-breathing T1-weighted radial 3D-GRE, the detec-
ion of pulmonary nodules was compared with that of PET-CT.
 total of 69 nodules, including 45 FDG-avid lesions, were
etected. The sensitivity of MR-PET was 70.3% for all nodules,
5.6% for FDG-avid nodules, and 88.6% for nodules 0.5 cm
n diameter or larger. There was a significantly strong corre-
ation between SUV quantitative data of pulmonary nodules
btained with PET-CT and that obtained with MR-PET (r  = 0.96,
 < 0.001).
A recent study comparing PET-CT and MR-PET demon-
trated the effectiveness of whole-body MR-PET in oncology
61] showing no significant differences between MR-PET and
ET-CT in regard to confidence and degree of agreement of
natomic lesion localization. In this study 227 tracer-avid lesions
ere identified in 50 patients. MR-PET imaging identified 2
dditional lesions. There was 10% improvement in local staging
ith MR-PET. The alignment was better for MR-PET imaging.
In another study, Pace et al. [67] compared whole-body
ET-CT and MR-PET regarding lesion detection and quanti-
ation of FDG uptake in lesions and in normal organ tissues
n breast cancer patients. Their study demonstrated that whole-
ody MR-PET was feasible in that clinical setting. MR-PET
howed equivalent performance to PET-CT and SUV measure-
ents correlated well (Fig. 6).
One study by Catalano et al. [68] compared the clinical impact
f combined MR-PET to that of combined PET-CT. The studies
ere performed in 134 patients with cancer, and showed that
ndings affecting clinical management were noted for PET-CT
tudies but not for MR-PET studies in 2/134 patients, and for
R-PET studies but not for PET-CT studies in 24/134 patients.
R-PET contributed to clinical management more often than
id PET-CT.
Intra-individual studies for specific conditions appear in
ewer numbers. In a study with 70 patients, Beiderwellen et al.
69] assessed the value of MR-PET using a whole-body protocol
or the depiction and characterization of liver lesions in com-
arison to PET-CT. They concluded that MR-PET, even in the
etting of a whole-body approach, provided higher lesion con-
picuity and diagnostic confidence, and might therefore evolve
s an alternative in oncologic imaging. Gaertner et al. [70]
ompared a short protocol using Dixon sequences for AC and
v
s
P
Pf Radiology Open 1 (2014) 28–39 35
natomic localization and compared 68Ga-DOTATOC MR-PET
ith PET-CT in patients with neuroendocrine tumors. The SUVs
f focal lesions did not differ between the PET-CT and MR-PET
cquisitions, and correlated in a linear fashion (ρ  = 0.90) and the
etectability of focal PET lesions was equivalent to PET-CT on
 patient basis and organ system basis.
Concerning the evaluation of malignant bone lesions (Fig. 7),
iber et al. [71] showed that whole-body MR-PET is technically
nd clinically robust for evaluation of bone lesions. Ninety-eight
one lesions were identified in 33 of 119 patients. Visual lesion
onspicuity was comparable for PET-CT and MR-PET. For bone
esions and regions of normal bone, a highly significant correla-
ion occurred between the mean SUVs for MR-PET and PET-CT
r = 0.950 and 0.917, respectively). MR-PET, including diag-
ostic T1-weighted TSE sequences, was superior to PET-CT
or anatomic delineation and allocation of bone lesions. These
bservations might be of clinical relevance in selected cases,
uch as in primary bone tumors and in routine oncologic protocol
or MR-PET.
One of the strongest evidence for a clinical indication of MR-
ET occurs in the head and neck cancer population (Fig. 8).
ue to frequent distant metastases the whole body approach of
ybrid MR-PET may be an advantage. Kuhn et al. [72] compared
ontrast-enhanced MR-PET imaging with contrast-enhanced
ET-CT in 150 consecutive patients referred for primary staging
r restaging of head and neck cancer. MR-PET had compara-
le image quality to CT and MR, and T2-weighted MR-PET
maging performed similarly, for metastatic lymph nodes, or
etter than contrast-enhanced PET/CT, for primary tumors, in
he morphologic characterization of PET-positive lesions. Study
esults provided evidence that MR-PET imaging could serve
s a legitimate alternative to PET-CT in the clinical workup of
atients with head and neck cancers. These results are partic-
larly important, as the interfaces between bone, air, and soft
issues in nasopharynx, oropharynx, and hypopharynx are con-
idered major challenges for MR-PET.
.  Pediatric  oncology
The use of PET-CT in pediatric oncology has increased
ramatically in the past decade. The main indications include
taging and monitoring of lymphomas, sarcomas, nasopha-
yngeal carcinoma, neuroblastoma, CNS-tumors, cancer of
nknown primary, and radiotherapy planning [34]. Additionally,
R-PET can be an alternative to PET-CT for longitudi-
al follow-up studies monitoring the therapeutic response to
hemotherapy.
MR-PET can be seen as a valuable alternative to PET-CT,
specially in pediatric population. The substitution of PET-CT
y MR-PET in these patients reduces the overall dose by the
raction of the CT scan multiplied by the individual necessary
umber of follow-up examinations per patient, while preser-
ing the advantages of hybrid imaging [17,34]. Potential dose
avings of up to 80% have been postulated when using MR-
ET instead of PET-CT in pediatric oncologic imaging [35].
atient exposure to radiation from complementary CT is a major
36 M. Ramalho et al. / European Journal of Radiology Open 1 (2014) 28–39
Fig. 6. Large left breast cancer with nodal metastasis. Axial DWI (A), ADC map (B), axial subtraction dynamic post-gadolinium 3D-GRE fat-suppressed T1-weighted
image (C), and axial post-gadolinium 3D-GRE fat-suppressed T1-weighted image (D). Axial PET (E) and fused PET-T1-weighted VIBE MR (F) images. There is
a large irregular mass involving the central region of the left breast, which demonstrates increased signal on the DWI (arrow, A) and low signal on the ADC map
(arrow, B) images, in keeping with a true restriction. The mass demonstrates intense enhancement (arrow, C–D), intense FDG uptake (arrow, E), in keeping with
aggressive breast cancer. There is also a small round ipsilateral internal mammary lymph node, which demonstrates similar signal characteristics and FDG uptake to
that of the primary breast mass (arrowhead, A–F) in keeping with a metastatic nodal disease. Patient also has evidence of ipsilateral axillary nodal metastatic disease
(not shown).
Fig. 7. Images of bone metastases in a patient with breast cancer. Axial unenhanced CT (A), PET (B), and PET-CT (C) images. Axial T2-weighted HASTE MR (D),
PET (E); fused PET-T2-weighted HASTE MR (F). Coronal STIR (G), PET (H), fused PET-STIR MR (I). Two bone metastases in the posterior acetabulum showing
intense uptake are seen on PET and PET-CT (arrows, C) and MR-PET. Equivalent detectability is perceived between unenhanced CT and HASTE datasets (A and
D). STIR images show improved morphologic characterization of PET-positive lesions (arrows, G).
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Fig. 8. Status post thyroidectomy in a patient with elevated thyroxine-binding globulin levels. Axial unenhanced CT (A), PET (B), and PET-CT (C) images. Axial
T2-weighted HASTE MR (D), PET (E), fused PET-T2-weighted HASTE MR (F). A mildly T2-weighted hyperintense nodule is seen adjacent to the right aspect of
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oncern in pediatrics, due to the risk of developing secondary
ancer [73–76] as survival of children with cancer has increased
onsiderably.
Although this is a new application and data are still sparse, the
rst indications support that MR-PET is a promising modality
or the clinical work-up of pediatric malignancies [35,77–79].
chuler et al. [80] presented their first experiences using com-
ined MR-PET for high-risk sarcomas. MR-PET contributed to
ecision-making, and helped to guide biopsies of large and het-
rogeneous tumors. Another study evaluating co-registration of
ET and MRI datasets for staging of pediatric cancers, found
R-PET to be the methodology of choice for adequate of single
umor detection and staging [81].
Prospective studies are needed comparing staging accuracy of
R-PET to that of PET-CT using the same radiotracer. Schäfer
t al. [82] compared MR-PET and PET-CT for lesion detection
nd interpretation, as well as quantification of FDG uptake and
ccuracy of MR-PET in pediatric patients with solid tumors.
hey showed that MR-PET was technically feasible; with satis-
actory performance for PET quantification with SUVs similar
o those of PET-CT. MR-PET demonstrated equivalent lesion
etection rates while offering markedly reduced radiation expo-
ure.
.  ConclusionMR-PET is a recent technique that offers the possibility
o assess anatomic, functional, and metabolic information in
ne examination. Although it offers the additional advantageodule is not seen on unenhanced CT images (A). Fused PET-CT and PET-MR
of this nodule a. HASTE images show improved morphologic characterization
f radiation-reduced examination, it needs to be further evalu-
ted against PET-CT. It is also important to evaluate if combined
R-PET scanners are economical viable compared to individual
ystems.
In order to achieve optimum impact and ensure clinical
cceptance of this exciting new technology, defined MR-PET
rotocols are necessary to make MR-PET fast enough to com-
ete with PET-CT, while providing additional clinical value over
ET-CT.
Current evidence shows overall good correlation between
ET-CT and MR-PET in lesion detection across most publica-
ions on oncologic diseases. Moreover, initial results in pediatric
atients are encouraging, particularly with the reduction in radi-
tion exposure.
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